

PHARMACEUTICAL 2022

Nuvation Bio Inc. Rank 17 of 466









PHARMACEUTICAL 2022

Nuvation Bio Inc. Rank 17 of 466



The relative strengths and weaknesses of Nuvation Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvation Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Nuvation Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 218% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	772,073
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,925
Liabilities, Non-Current	2,192
Other Assets	3,292
Other Compr. Net Income	-2,742
Other Expenses	0
Other Liabilities	11,037
Other Net Income	6,470
Other Revenues	0
Property and Equipment	786
Research and Development	69,037
Selling, General and Administrative Expense	24,281

Output Variable	Value in 1000 USD
Assets	776,151
Liabilities	30,154
Expenses	93,318
Revenues	0
Stockholders Equity	745,997
Net Income	-86,848
Comprehensive Net Income	-88,219
Economic Capital Ratio	296%

